GlassScriptPhysician profile
Laura Pendlebury
NPI 1265416812
$1,319.88
in general payments reported to CMS, 2019-2025
23 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $36.86 · 2021: $169 · 2022: $351 · 2023: $207 · 2024: $143 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $255.75 | 2019-2023 | |
| Exeltis, USA INC. | $152.24 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $132.80 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $119.89 | 2023-2025 | Myfembree |
| Biogen, INC. | $106.58 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $86.33 | 2019-2023 | |
| Astellas Pharma US INC | $85.84 | 2024-2025 | Veozah |
| Myovant Sciences INC. | $54.43 | 2021-2022 | |
| Agile Therapeutics, INC. | $52.82 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.34 | 2022 | |
| Therapeuticsmd, INC. | $32.15 | 2019-2021 | |
| Pfizer INC. | $26.29 | 2025 | |
| Hologic Sales and Service, LLC | $22.59 | 2019 | |
| Organon LLC | $17.89 | 2024 | |
| Coopersurgical, INC. | $17.37 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $16.82 | 2022 | |
| Novo Nordisk INC | $16.27 | 2024 | Wegovy |
| Renovia INC | $15.70 | 2021 | |
| Shield Therapeutics INC | $14.66 | 2024 | |
| Avion Pharmaceuticals | $14.65 | 2022 | |
| Millicent US INC | $13.65 | 2024 | Femring, Intrarosa |
| Evofem Biosciences, INC. | $11.95 | 2021 | |
| Scynexis, INC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Pendlebury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.